- Home
- TAC vs MLTX Comparison
TAC vs MLTX Comparison
Compare TAC & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAC
- MLTX
- Stock Information
- Founded
- TAC 1909
- MLTX 2021
- Country
- TAC Canada
- MLTX Switzerland
- Employees
- TAC N/A
- MLTX N/A
- Industry
- TAC Electric Utilities: Central
- MLTX Biotechnology: Pharmaceutical Preparations
- Sector
- TAC Utilities
- MLTX Health Care
- Exchange
- TAC Nasdaq
- MLTX Nasdaq
- Market Cap
- TAC 3.2B
- MLTX 2.8B
- IPO Year
- TAC N/A
- MLTX N/A
- Fundamental
- Price
- TAC $13.14
- MLTX $51.18
- Analyst Decision
- TAC Buy
- MLTX Strong Buy
- Analyst Count
- TAC 3
- MLTX 7
- Target Price
- TAC $19.83
- MLTX $74.83
- AVG Volume (30 Days)
- TAC 946.1K
- MLTX 732.8K
- Earning Date
- TAC 11-04-2025
- MLTX 11-06-2025
- Dividend Yield
- TAC 1.36%
- MLTX N/A
- EPS Growth
- TAC N/A
- MLTX N/A
- EPS
- TAC N/A
- MLTX N/A
- Revenue
- TAC $1,838,165,207.00
- MLTX N/A
- Revenue This Year
- TAC N/A
- MLTX N/A
- Revenue Next Year
- TAC N/A
- MLTX N/A
- P/E Ratio
- TAC N/A
- MLTX N/A
- Revenue Growth
- TAC N/A
- MLTX N/A
- 52 Week Low
- TAC $7.82
- MLTX $31.42
- 52 Week High
- TAC $14.64
- MLTX $61.87
- Technical
- Relative Strength Index (RSI)
- TAC 67.73
- MLTX 38.79
- Support Level
- TAC $11.94
- MLTX $51.45
- Resistance Level
- TAC $13.02
- MLTX $61.30
- Average True Range (ATR)
- TAC 0.29
- MLTX 2.88
- MACD
- TAC 0.07
- MLTX -0.85
- Stochastic Oscillator
- TAC 89.85
- MLTX 3.08
About TAC TransAlta Corporation
TransAlta Corp is an independent power producer based in Alberta, Canada. The company operates a diverse and growing fleet of electrical power generation assets in Canada, the United States, and Australia. The company has six reportable segments namely, Hydro, Wind & Solar, Energy Marketing, Gas, Energy Transition segment and Corporate Segment. The company generates the majority of its revenue from the gas segment.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.